RNF43 p.G659fs 通过 PI3K/AKT/mTOR 信号通路和 HLA-E 上调导致 MSI-high 结直肠癌中 NK 细胞功能障碍
RNF43 p.G659fs leads to natural killer cell dysfunction in MSI-high colorectal cancer through PI3K/AKT/mTOR signaling and HLA-E up-regulation.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Context-dependent rewiring of the cGAS-STING pathway in cancer: Implications for immunotherapy and therapeutic resistance.
Context-dependent rewiring of the cGAS-STING pathway in cancer: Implications for immunotherapy and therapeutic resistance.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
cGAS-STING通路是一个关键的胞质DNA感知系统,连接固有免疫与适应性免疫,可检测来自细胞核、线粒体或病原体的双链DNA,触发2'3'-cGAMP的产生,从而激活干扰素基因刺激因子(STING),诱导I型干扰素和促炎细胞因子。在其经典作用中,该轴促进树突状细胞成熟、抗原交叉呈递以及细胞毒性T细胞和自然杀伤(NK)细胞的募集,将“冷”肿瘤转化为“热”免疫应答性病灶。本综述提出,cGAS-STING是一种情境依赖性调节因子。急性激活可增强抗肿瘤监视,而肿瘤微环境(TME)内慢性或错误导向的信号传导则矛盾性地促进进展和治疗耐药。在基因组不稳定或经治疗暴露的肿瘤中,持续性cGAS-STING活性驱动慢性炎症,上调PD-L1等检查点,并扩增免疫抑制性细胞群,如髓源性抑制细胞(MDSCs)和调节性T细胞(Tregs)。该通路的输出进一步受到代谢和表观遗传重编程的塑造。本综述还讨论了下一代激动剂和拮抗剂的开发,以及为脉冲式或区室限制性激活设计的精准递送系统。利用cGAS-STING的免疫刺激潜力,同时减轻其在适应性耐药中的作用,对于改善多种癌症类型的临床结局至关重要。
The cGAS-STING pathway is a critical cytosolic DNA-sensing system that bridges innate and adaptive immunity, which detects double-stranded DNA from nuclear, mitochondrial, or pathogen sources, triggering the production of 2'3'-cGAMP thereby activating the Stimulator of Interferon Genes (STING), inducing type I interferons and pro-inflammatory cytokines. In its canonical role, this axis facilitates dendritic cell maturation, antigen cross-presentation, and the recruitment of cytotoxic T and natural killer (NK) cells, converting "cold" tumors into "hot" immune-responsive lesions. This review posits that cGAS-STING is a context-dependent regulator. While acute activation bolsters anti-tumor surveillance, chronic or misdirected signaling within the tumor microenvironment (TME) paradoxically promotes progression and treatment resistance.
In genomically unstable or therapy-exposed tumors, persistent cGAS-STING activity drives chronic inflammation, upregulates checkpoints like PD-L1, and expands immunosuppressive populations, such as myeloid-derived suppressor cells (MDSCs) and regulatory T cells (Tregs). The pathway's output is further shaped by metabolic and epigenetic reprogramming.
The review also discusses the development of next-generation agonists and antagonists, alongside precision delivery systems designed for pulsed or compartment-restricted activation. Harnessing the immunostimulatory potential of cGAS-STING while mitigating its role in adaptive resistance is essential for improving clinical outcomes across diverse cancer types.
MEMBER ACCOUNT
登录成功会直接打开下一页。